Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs EXELDERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Apply a thin layer to affected skin twice daily (morning and evening).
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Not extensively metabolized; minimal systemic absorption after topical application.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Approximately 89–93% bound to plasma proteins, primarily albumin.
Not applicable; systemic levels are undetectable with topical use.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
Not applicable; negligible systemic absorption.
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
No dosage adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
No dosage adjustment required for hepatic impairment.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
None
None.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Known hypersensitivity to imidazole antifungals or any component of the formulation
Known hypersensitivity to sulconazole or any component of the formulation.
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
None known.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs EXELDERM, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and EXELDERM depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and EXELDERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.